Advent and GIC make USD 8bn bid for Swedish biotech firm

The bid may open the door to a rival bid from a drugmaker, said Per Colleen, head of fundamental equities at Swedish state pension fund AP4, which owns about 7 percent of the biotech firm.
Per Colleen, head of equities, AP4 | Photo: PR / AP4/Peter Phillips
Per Colleen, head of equities, AP4 | Photo: PR / AP4/Peter Phillips
BY THOMAS MULIER, BLOOMBERG

Private equity firm Advent International and Singapore wealth fund GIC have agreed to buy drugmaker Swedish Orphan Biovitrum AB for USD 8bn, in the largest buyout of a Nordic company in more than five years - provided a larger bid doesn't appear.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading